13 citations
,
August 2016 in “Reproduction” High doses of nandrolone decanoate disrupt ovarian hormones and receptors in rats, with recovery only at lower doses and longer recovery times.
8 citations
,
March 2008 in “Deutsche medizinische Wochenschrift/Deutsche Medizinische Wochenschrift” Adding estrogen increased bone mass in a transsexual man undergoing hormone therapy.
7 citations
,
October 1974 in “PubMed” Topical estrogens improved hair growth in about half of the patients.
16 citations
,
October 2007 in “Andrologia” DHT is a strong androgen that may pose less risk to the prostate compared to testosterone.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
August 2024 in “medRxiv (Cold Spring Harbor Laboratory)” Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
36 citations
,
June 2001 in “Neuroscience Letters” Finasteride may affect fetal brain development and increase arousal, but more research is needed for safety confirmation.
100 citations
,
April 1990 in “The Journal of Clinical Endocrinology & Metabolism” The ovary mainly causes high testosterone in PCO, while the adrenal gland is the main source in IH.
56 citations
,
April 1998 in “Steroids” Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
The FDA did not approve a testosterone drug because of safety concerns.
Testosterone pellet therapy may better address hormone imbalances in aging by focusing on local hormone production and symptom relief.
9 citations
,
November 2008 in “Journal of Womens Health” Researchers had trouble finding enough participants for a trial on DHEA's effects on postmenopausal women's sexual desire.
December 2012 in “Journal of Dermatological Science” Estrogen increases a growth factor in hair cells which might affect hair loss.
52 citations
,
April 2002 in “Brain Research” Lower allopregnanolone levels increase stress-related dopamine release in the brain.
January 1983 in “Elsevier eBooks” Masculinization in affected individuals occurs gradually after puberty due to hormone changes.
35 citations
,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
January 2017 in “Revista da Universidade Vale do Rio Verde” Finasteride is commonly used for male pattern hair loss but has potential risks, including irreversible sexual dysfunction.
11 citations
,
September 2012 in “Journal of obstetrics and gynaecology Canada” Testosterone therapy seems safe for short-term use in postmenopausal women with low sexual desire, but more research on long-term effects is needed.
May 2020 in “International Journal of Clinical Obstetrics and Gynaecology” The combined therapy improved symptoms in PCOS patients.
4 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Finasteride use in young men with hair loss is linked to sexual dysfunction.
3 citations
,
February 2017 in “Archives of Medical Science” Finasteride treatment changes Cx43 in rat testes, possibly causing fertility issues.
2 citations
,
November 2012 in “InTech eBooks” The document concludes that sex hormones are crucial for mammalian reproduction, health, and behavior, and require more research for therapeutic use.
January 2025 in “HORMONES” Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.
7 citations
,
December 2017 in “Journal of the European Academy of Dermatology and Venereology” Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
December 1990 in “PubMed” Topical 17 alpha-propylmesterolone increases hair cell growth in androgenetic alopecia.
9 citations
,
October 2017 in “Molecular Medicine Reports” Finasteride causes reduced tear flow and severe eye inflammation.
August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.